93 related articles for article (PubMed ID: 8927682)
1. Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: a pilot study.
Berman I; Merson A; Sison C; Allan E; Schaefer C; Loberboym M; Losonczy MF
Psychopharmacol Bull; 1996; 32(1):95-100. PubMed ID: 8927682
[TBL] [Abstract][Full Text] [Related]
2. Early effects of treatment on regional cerebral blood flow in first episode schizophrenia patients evaluated with 99Tc-ECD-SPECT.
Novak B; Milcinski M; Grmek M; Kocmur M
Neuro Endocrinol Lett; 2005 Dec; 26(6):685-9. PubMed ID: 16380684
[TBL] [Abstract][Full Text] [Related]
3. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics.
Sabri O; Erkwoh R; Schreckenberger M; Cremerius U; Schulz G; Dickmann C; Kaiser HJ; Steinmeyer EM; Sass H; Buell U
J Nucl Med; 1997 Feb; 38(2):181-8. PubMed ID: 9025731
[TBL] [Abstract][Full Text] [Related]
4. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naïve schizophrenic patients: correlations with symptom change.
Ngan ET; Lane CJ; Ruth TJ; Liddle PF
J Neurol Neurosurg Psychiatry; 2002 Jan; 72(1):106-10. PubMed ID: 11784835
[TBL] [Abstract][Full Text] [Related]
5. Regional cerebral blood flow in late-onset schizophrenia: a SPECT study using 99mTc-HMPAO.
Sachdev P; Brodaty H; Rose N; Haindl W
Schizophr Res; 1997 Oct; 27(2-3):105-17. PubMed ID: 9416641
[TBL] [Abstract][Full Text] [Related]
6. The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: relationship with treatment response.
Ertugrul A; Volkan-Salanci B; Basar K; Karli Oguz K; Demir B; Ergun EL; Senturk S; Erbas B; Cila A; Ulug B
Psychiatry Res; 2009 Nov; 174(2):121-9. PubMed ID: 19837567
[TBL] [Abstract][Full Text] [Related]
7. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
8. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics.
Sabri O; Erkwoh R; Schreckenberger M; Owega A; Sass H; Buell U
Lancet; 1997 Jun; 349(9067):1735-9. PubMed ID: 9193384
[TBL] [Abstract][Full Text] [Related]
9. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
10. Regional cerebral blood flow in schizophrenia before and after neuroleptic medication.
Yildiz A; Eryilmaz M; Gungor F; Erkilic M; Karayalcin B
Nucl Med Commun; 2000 Dec; 21(12):1113-8. PubMed ID: 11200015
[TBL] [Abstract][Full Text] [Related]
11. Hypofrontality and negative symptoms in major depressive disorder.
Galynker II; Cai J; Ongseng F; Finestone H; Dutta E; Serseni D
J Nucl Med; 1998 Apr; 39(4):608-12. PubMed ID: 9544664
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
13. An open study of risperidone liquid in the acute phase of schizophrenia.
Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
[TBL] [Abstract][Full Text] [Related]
14. [Differences in cerebral blood flow following risperidone treatment in children with autistic disorder].
Ozdemir DF; Karabacak NI; Akkaş B; Akdemir O; Unal F; Senol S
Turk Psikiyatri Derg; 2009; 20(4):346-56. PubMed ID: 20013426
[TBL] [Abstract][Full Text] [Related]
15. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.
Siegel BV; Buchsbaum MS; Bunney WE; Gottschalk LA; Haier RJ; Lohr JB; Lottenberg S; Najafi A; Nuechterlein KH; Potkin SG
Am J Psychiatry; 1993 Sep; 150(9):1325-36. PubMed ID: 8352343
[TBL] [Abstract][Full Text] [Related]
16. Psychopathological and SPECT findings in never-treated schizophrenia.
Erkwoh R; Sabri O; Steinmeyer EM; Bull U; Sass H
Acta Psychiatr Scand; 1997 Jul; 96(1):51-7. PubMed ID: 9259224
[TBL] [Abstract][Full Text] [Related]
17. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
Bondolfi G; Dufour H; Patris M; May JP; Billeter U; Eap CB; Baumann P
Am J Psychiatry; 1998 Apr; 155(4):499-504. PubMed ID: 9545995
[TBL] [Abstract][Full Text] [Related]
18. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
Hwang TJ; Lee SM; Sun HJ; Lin HN; Tsai SJ; Lee YC; Chen YS
J Formos Med Assoc; 2003 Jan; 102(1):30-6. PubMed ID: 12684609
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
20. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.
Molina V; Taboada D; Aragüés M; Hernández JA; Sanz-Fuentenebro J
Schizophr Res; 2014 Sep; 158(1-3):223-9. PubMed ID: 25088730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
